Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Dr. Harish Seethamraju

Total: 14 projects

  1. H-16888 — Vibration response imaging in patients with acute respiratory symptoms. Protocol DB016 Role: Co-I Harish Seethamraju

  2. H-17325 — ACS004: An open-label treatment use of (Cyclosporine, USP), inhalation solution (Pulminiq) following lung transplantation. Role: Co-I Harish Seethamraju

  3. H-9795SCO30003 — A multicenter, randomized, double-blind, parallel group, placebo-controlled study investigate the long-term effects of salmeterol/fluticasone propoinate (seretide TM/viani (TM)/Advair (TM) 50/500UG-BD, all delivered via the diskus (TM)/accuhaler (TM) inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over three years of treatment. Role: Co-I Harish Seethamraju

  4. H-12876 — (The “LOCCS” Trial). The leukotriene modifier or corticosteroids or corticosteroids-Salmeterol trial. Role: Co-I Harish Seethamraju

  5. H-15025 — Study of acid reflux and asthma (SAA). Role: Co-I Harish Seethamraju

  6. H-15483 — Comparison of a Tacrolimus/Sirolimus/Prednisone regimen versus tacrolimus/Azathioprine/Prednisone immunosuppressive regimen
    in lung transplantation. Role: Co-I Harish Seethamraju

  7. H-15505 — Multiple modality antibody reduction in highly sensitized lung transplant candidates. Role: Co-I Harish Seethamraju

  8. H-16218 — Photopheresis for the management of rejection in lung transplant recipients: A retrospective analysis. Role: Co-I Harish Seethamraju

  9. H-16812 — (COPD AQ) Chronic obstructive pulmonary disease assessment questionnaire. Role: Co-I Harish Seethamraju

  10. H-17036 — Spectrum of intravenous immunoglobulin (IVIG) use in inpatient lung transplant recipients. Role: Co-I Harish Seethamraju

  11. H-16193 — SCO40043. A randomized, double-blind, parallel group, 52-week study to compare the effect of the fluticasone propionate/salmeterol diskus combination product 250/50mcg bid with Salmeterol discus 50mcg bid on the annual rate of moderate/severe exacerbation in subjects with chronic obstructive pulmonary disease (COPD). Role: Co-I Harish Seethamraju

  12. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN RSV01 Plus Standard of Care in Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) (H# not available yet).

  13. A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY OF AN ANTI-T-LYMPHOCYTE IMMUNE GLOBULIN (EZ-2053) IN THE PROPHYLAXIS OF ACUTE PULMONARY REJECTION IN ADULT RECIPIENTS OF PRIMARY PULMONARY ALLOGRAFT(S) (H-19893)

  14. PULMONARY HYPERTENSION BREAKTHROUGH INITIATIVE (PHBI) (H-18981)